« Back
Home /
PEG2000-C-DMG

PEG2000-C-DMG

Item no.	HY-145411-10mM
Manufacturer	MedChem Express
Amount	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 25 mg 500 mg 50 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	98.0
Citations	[1]Garber K. Alnylam launches era of RNAi drugs. Nat Biotechnol. 2018;36(9):777-778. \|[2]Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):11-21.
Smiles	CCCCCCCCCCCCCC(O[C@@H](COC(NCCCOCCOC)=O)COC(CCCCCCCCCCCCC)=O)=O.[45]
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Shipping Condition	Cool pack
Available
Manufacturer - Type	Oligonucleotides
Manufacturer - Applications	Metabolism-sugar/lipid metabolism
Manufacturer - Targets	Liposome
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, stored under nitrogen)
Molecular Weight	2610.29
Product Description	PEG2000-C-DMG, a pegylated lipid, can be used for the preparation of Onpattro. Onpattro, a hepatically directed investigational RNAi therapeutic agent, harnesses this process to reduce the production of mutant and wild-type transthyretin by targeting the 3′ untranslated region of transthyretin mRNA[1][2].
Manufacturer - Research Area	Endocrinology
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Metabolic Enzyme/Protease
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-145411-10mM-safety-datasheet.pdf